vs
Archrock, Inc.（AROC）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
Archrock, Inc.的季度营收约是REPLIGEN CORP的1.9倍（$377.1M vs $197.9M），Archrock, Inc.净利率更高（31.0% vs 6.7%，领先24.3%），Archrock, Inc.同比增速更快（15.5% vs 13.6%），Archrock, Inc.自由现金流更多（$126.7M vs $17.6M），过去两年Archrock, Inc.的营收复合增速更高（18.5% vs 14.4%）
Archrock, Inc. 是领先的天然气压缩服务及相关设备解决方案供应商，主要服务北美油气领域，核心业务涵盖压缩系统租赁、维护、售后支持及销售，覆盖上游生产、中游运输与天然气加工板块。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
AROC vs RGEN — 直观对比
营收规模更大
AROC
是对方的1.9倍
$197.9M
营收增速更快
AROC
高出1.9%
13.6%
净利率更高
AROC
高出24.3%
6.7%
自由现金流更多
AROC
多$109.1M
$17.6M
两年增速更快
AROC
近两年复合增速
14.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $377.1M | $197.9M |
| 净利润 | $116.8M | $13.3M |
| 毛利率 | 53.0% | 52.5% |
| 营业利润率 | 39.4% | 9.0% |
| 净利率 | 31.0% | 6.7% |
| 营收同比 | 15.5% | 13.6% |
| 净利润同比 | 95.4% | 143.9% |
| 每股收益（稀释后） | $0.67 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AROCRGEN
| Q4 25 | $377.1M | $197.9M | ||
| Q3 25 | $382.4M | $188.8M | ||
| Q2 25 | $383.2M | $182.4M | ||
| Q1 25 | $347.2M | $169.2M | ||
| Q4 24 | $326.4M | $174.1M | ||
| Q3 24 | $292.2M | $154.9M | ||
| Q2 24 | $270.5M | $154.1M | ||
| Q1 24 | $268.5M | $151.3M |
净利润AROCRGEN
| Q4 25 | $116.8M | $13.3M | ||
| Q3 25 | $71.2M | $14.9M | ||
| Q2 25 | $63.4M | $14.9M | ||
| Q1 25 | $70.8M | $5.8M | ||
| Q4 24 | $59.8M | $-30.3M | ||
| Q3 24 | $37.5M | $-654.0K | ||
| Q2 24 | $34.4M | $3.3M | ||
| Q1 24 | $40.5M | $2.1M |
毛利率AROCRGEN
| Q4 25 | 53.0% | 52.5% | ||
| Q3 25 | 48.5% | 53.2% | ||
| Q2 25 | 45.4% | 50.0% | ||
| Q1 25 | 47.4% | 53.6% | ||
| Q4 24 | 46.3% | 26.1% | ||
| Q3 24 | 44.4% | 50.0% | ||
| Q2 24 | 41.5% | 49.8% | ||
| Q1 24 | 42.1% | 49.5% |
营业利润率AROCRGEN
| Q4 25 | 39.4% | 9.0% | ||
| Q3 25 | 25.3% | 8.9% | ||
| Q2 25 | 22.5% | 7.6% | ||
| Q1 25 | 26.5% | 3.9% | ||
| Q4 24 | 24.0% | -17.7% | ||
| Q3 24 | 18.1% | -5.1% | ||
| Q2 24 | 17.6% | 1.0% | ||
| Q1 24 | 20.0% | 1.3% |
净利率AROCRGEN
| Q4 25 | 31.0% | 6.7% | ||
| Q3 25 | 18.6% | 7.9% | ||
| Q2 25 | 16.6% | 8.2% | ||
| Q1 25 | 20.4% | 3.4% | ||
| Q4 24 | 18.3% | -17.4% | ||
| Q3 24 | 12.8% | -0.4% | ||
| Q2 24 | 12.7% | 2.2% | ||
| Q1 24 | 15.1% | 1.4% |
每股收益（稀释后）AROCRGEN
| Q4 25 | $0.67 | $0.24 | ||
| Q3 25 | $0.40 | $0.26 | ||
| Q2 25 | $0.36 | $0.26 | ||
| Q1 25 | $0.40 | $0.10 | ||
| Q4 24 | $0.35 | $-0.55 | ||
| Q3 24 | $0.22 | $-0.01 | ||
| Q2 24 | $0.22 | $0.06 | ||
| Q1 24 | $0.26 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.6M | $767.6M |
| 总债务越低越好 | — | $542.2M |
| 股东权益账面价值 | $1.5B | $2.1B |
| 总资产 | $4.3B | $2.9B |
| 负债/权益比越低杠杆越低 | — | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资AROCRGEN
| Q4 25 | $1.6M | $767.6M | ||
| Q3 25 | $4.1M | $748.7M | ||
| Q2 25 | $5.9M | $708.9M | ||
| Q1 25 | $4.8M | $697.2M | ||
| Q4 24 | $4.4M | $757.4M | ||
| Q3 24 | $3.7M | $784.0M | ||
| Q2 24 | $919.0K | $809.1M | ||
| Q1 24 | $1.2M | $780.6M |
总债务AROCRGEN
| Q4 25 | — | $542.2M | ||
| Q3 25 | — | $537.9M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $525.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益AROCRGEN
| Q4 25 | $1.5B | $2.1B | ||
| Q3 25 | $1.4B | $2.1B | ||
| Q2 25 | $1.4B | $2.1B | ||
| Q1 25 | $1.3B | $2.0B | ||
| Q4 24 | $1.3B | $2.0B | ||
| Q3 24 | $1.3B | $2.0B | ||
| Q2 24 | $894.5M | $2.0B | ||
| Q1 24 | $882.1M | $2.0B |
总资产AROCRGEN
| Q4 25 | $4.3B | $2.9B | ||
| Q3 25 | $4.4B | $2.9B | ||
| Q2 25 | $4.4B | $2.9B | ||
| Q1 25 | $4.0B | $2.9B | ||
| Q4 24 | $3.8B | $2.8B | ||
| Q3 24 | $3.8B | $2.8B | ||
| Q2 24 | $2.7B | $2.9B | ||
| Q1 24 | $2.7B | $2.8B |
负债/权益比AROCRGEN
| Q4 25 | — | 0.26× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.27× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $214.5M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | $126.7M | $17.6M |
| 自由现金流率自由现金流/营收 | 33.6% | 8.9% |
| 资本支出强度资本支出/营收 | 23.3% | 4.1% |
| 现金转化率经营现金流/净利润 | 1.84× | 1.93× |
| 过去12个月自由现金流最近4个季度 | $119.6M | $93.9M |
8季度趋势，按日历期对齐
经营现金流AROCRGEN
| Q4 25 | $214.5M | $25.7M | ||
| Q3 25 | $164.5M | $48.1M | ||
| Q2 25 | $127.5M | $28.6M | ||
| Q1 25 | $115.6M | $15.0M | ||
| Q4 24 | $124.3M | $39.2M | ||
| Q3 24 | $96.9M | $49.3M | ||
| Q2 24 | $70.7M | $42.2M | ||
| Q1 24 | $137.7M | $44.7M |
自由现金流AROCRGEN
| Q4 25 | $126.7M | $17.6M | ||
| Q3 25 | $29.5M | $43.4M | ||
| Q2 25 | $16.0M | $21.5M | ||
| Q1 25 | $-52.5M | $11.4M | ||
| Q4 24 | $26.4M | $33.6M | ||
| Q3 24 | $26.9M | $42.3M | ||
| Q2 24 | $-20.6M | $37.4M | ||
| Q1 24 | $37.9M | $36.4M |
自由现金流率AROCRGEN
| Q4 25 | 33.6% | 8.9% | ||
| Q3 25 | 7.7% | 23.0% | ||
| Q2 25 | 4.2% | 11.8% | ||
| Q1 25 | -15.1% | 6.8% | ||
| Q4 24 | 8.1% | 19.3% | ||
| Q3 24 | 9.2% | 27.3% | ||
| Q2 24 | -7.6% | 24.3% | ||
| Q1 24 | 14.1% | 24.0% |
资本支出强度AROCRGEN
| Q4 25 | 23.3% | 4.1% | ||
| Q3 25 | 35.3% | 2.5% | ||
| Q2 25 | 29.1% | 3.9% | ||
| Q1 25 | 48.4% | 2.1% | ||
| Q4 24 | 30.0% | 3.2% | ||
| Q3 24 | 24.0% | 4.5% | ||
| Q2 24 | 33.7% | 3.1% | ||
| Q1 24 | 37.2% | 5.5% |
现金转化率AROCRGEN
| Q4 25 | 1.84× | 1.93× | ||
| Q3 25 | 2.31× | 3.23× | ||
| Q2 25 | 2.01× | 1.92× | ||
| Q1 25 | 1.63× | 2.57× | ||
| Q4 24 | 2.08× | — | ||
| Q3 24 | 2.58× | — | ||
| Q2 24 | 2.05× | 12.70× | ||
| Q1 24 | 3.40× | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AROC
| Horsepower Group Three | $112.6M | 30% |
| Horsepower Group Two | $108.5M | 29% |
| Horsepower Group One | $105.9M | 28% |
| Services | $32.9M | 9% |
| Over Counter Parts And Component Sales | $17.0M | 5% |
| Transferred At Point In Time | $1.4M | 0% |
RGEN
暂无分部数据
